Cowen & Company Initiates Coverage on Seres Therapeutics Inc(NASDAQ:MCRB). The shares have been rated Outperform. The rating by Cowen & Company was issued on Jun 6, 2016.
In a different note, FBR Capital said it Initiates Coverage on Seres Therapeutics Inc, according to a research note issued on Mar 30, 2016. The shares have been rated ‘Outperform’ by the firm.
Seres Therapeutics Inc (MCRB) made into the market gainers list on Fridays trading session with the shares advancing 2.63% or 0.86 points. Due to strong positive momentum, the stock ended at $33.53, which is also near the day’s high of $33.75. The stock began the session at $31.9 and the volume stood at 2,61,438 shares. The 52-week high of the shares is $52 and the 52 week low is $21.12. The company has a current market capitalization of $1,325 M and it has 3,95,19,842 shares in outstanding.
Seres Therapeutics Inc(MCRB) last announced its earnings results on May 16, 2016 for Fiscal Year 2016 and Q1.Company reported revenue of $2.71M. Analysts had an estimated revenue of $1.25M. Earnings per share were $-0.50. Analysts had estimated an EPS of $-0.48.
Several Insider Transactions has been reported to the SEC. On Jun 3, 2016, John G. Aunins (Chief Technology Officer & EVP) sold 14,015 shares at $30.30 per share price.Also, On Jun 2, 2016, David N Cook (Chief Scientific Officer & EVP) sold 16,000 shares at $29.43 per share price.On Jun 2, 2016, Roger Pomerantz (President and CEO) sold 70,951 shares at $30.39 per share price, according to the Form-4 filing with the securities and exchange commission.
Seres Therapeutics Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a range of biological drugs Ecobiotic microbiome therapeutics. It is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome in the human body. Its products include SER-109 which is designed to prevent further recurrences of Clostridium difficile infection (CDI) a debilitating infection of the colon; SER-109; SER-262 and SER-155. It’s SER-262 is a multi-strain Ecobiotic microbiome therapeutic to be used following antibiotic treatment of primary CDI to prevent an initial recurrence of CDI. The Company is developing SER-287 to treat ulcerative colitis. It is developing SER-155 which is an Ecobiotic microbiome therapeutic to treat enteric pathogens.